T1	Participants 58 83	myelodysplastic disorders
T2	Participants 229 274	patients with myelodysplastic syndromes (MDS)
T3	Participants 276 331	Sixty-eight evaluable patients with MDS were randomized
T4	Participants 931 1009	Approximately 30% of patients in both groups had progression of their disease,
